Wed 18 Nov 2026 08:07:25 BST
Search Company
*

Active Substance
New Active Substance
Search Site
--
*

Create Site
--
*
*
*
*
*
*
Update Site
Current data stored in EudraGMDP databaseCurrent data stored in OMS
--
Characters remaining:4000/4000
New Active Substance Importation
Active Substance*
Active Substance (English):
Active Substance (NL):
NCA Reference Key:
3rd Country Manufacturer
3rd Country ManufacturerOMS Location IdentifierOMS Organisation IdentifierLegal AddressNCA Reference KeyConfidentialEditDelete
No records found.

3rd Country Distributor
3rd Country DistributorOMS Location IdentifierOMS Organisation IdentifierLegal AddressNCA Reference KeyConfidentialEditDelete
No records found.

Information Messages
  • The WDA has been withdrawn, withdrawn date is: 2025-10-24
  • RTF Template


    Norwegian Medical Products Agency

    UNION FORMAT FOR A WHOLESALE DISTRIBUTION AUTHORISATION

    Human medicinal products and Veterinary medicinal products


    1. Authorisation Number

    :

    25/10773-4

    2. Name of Authorisation Holder

    :

    Norsk Medisinaldepot AS

    (ORG-100013274 / LOC-100018522)

    3. Address(es) of Site(s)

    :

    Alf Bjerckes Vei 28, Oslo, 0596, Norway 




    4. Legally registered address of Authorisation Holder

    :

    Alf Bjerckes Vei 28, Oslo, 0596

    5. Scope of authorisation

    :

    ANNEX 1

    6. Legal basis of authorisation

    :

    Art. 77(1) of Directive 2001/83/EC
    Art. 99 of Regulation (EU) 2019/6

    7. Name of responsible officer of the competent authority of the member state granting the wholesale distribution authorisation

    :

    Confidential, Confidential

    8. Signature

    :


    9. Date

    :

    2025-06-25

    10. Annexes attached

    :

    Annex 1 Scope of wholesale distribution authorisation

    Annex 2 (Optional) Address(es) of contract wholesale distribution sites and their authorisation number

    Annex 3 (Optional) Name(s) of responsible person(s)

    Annex 4 (Optional) Date of Inspection on which authorisation was granted

    Annex 5 (Optional) Additional provisions based on national requirements


    ANNEX 1

    SCOPE OF WHOLESALE DISTRIBUTION AUTHORISATION



    Name and address of the site: Norsk Medisinaldepot AS

    (ORG-100013274 / LOC-100018522)

    , Alf Bjerckes Vei 28, Oslo, 0596, Norway   



    Human medicinal products

    Veterinary medicinal products


    1. MEDICINAL PRODUCTS

       1.1. with a Marketing Authorisation or registration in EEA country(s)

       1.2. without a Marketing Authorisation or registration in the EEA and intended for EEA market*

       1.3. without a Marketing Authorisation or registration in the EEA and intended for exportation


    2. AUTHORISED WHOLESALE DISTRIBUTION OPERATIONS

       2.1. Procurement 

       2.2. Holding 

       2.3. Supply 

       2.4. Export 

       2.5. Other activities(s): (please specify) Storage of unreleased medicinal products in quarantine.


    3. MEDICINAL PRODUCTS WITH ADDITIONAL REQUIREMENTS

       3.1. Narcotic or psychotropic products** 

       3.2. Products requiring low temperature handling 

         3.2.1. Temperatures between 2 to 8 °C 

         3.2.2. Other temperatures: (please specify) Minus 10 to minus 25 degrees Celscius

       3.3. Other products: (please specify here or make a reference to Annex 5) API | Medicinal products derived from blood | Immunological medicinal products




    Any restrictions or clarifying remarks (for all users):  Section 1.2 applies only to:
    • For human medicinal products: Medicinal products for which NoMA has granted an exemption from the requirement for marketing authorisation (MA) through approval for compassionate use, named patient (CUNP), under current regulations, cf. the Medicines Regulation § 2-5, or authorisation for the sale of foreign language packages in a shortage situation.
    • For veterinary medicinal products: Medicinal products for which NoMA has granted an exemption from the requirement for MA, cf. the Regulation on Medicines for Animals, Chapter 4 and § 11-2, the Medicines Act § 2 d last paragraph, and Regulation 2019/6/EU Articles 112-114.

    The above-mentioned medicinal products are limited to patients/animals in Norway who/that have been granted such exemptions.

    For more specific details; see restrictions or clarifying remarks in WDA issued by NoMA.

    Section 2.2 also includes holding on behalf of other companies.



    *Art. 5 of Directive 2001/83/EC, Art. 83 of Regulation (EC) 726/2004 and Art. 110 of Regulation 2019/6.

    **Without prejudice to further authorisations as may be required according to national legislation.






    Reason for Withdrawing:

    Replaced by updated version.








    Union Format for a Wholesale Distribution Authorisation

    25/10773-4


    Page 1





    Loading, please wait